DCM
TAK icon

DGS Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

DGS Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$428K Buy
23,106
+8,936
+63% +$157K 0.07% 277
2025
Q4 		$221K Sell
14,170
-2,999
-17% -$42.9K 0.04% 431
2025
Q3 		$251K Sell
17,169
-45
-0.3% -$668 0.05% 327
2025
Q2 		$266K Buy
17,214
+174
+1% +$2.57K 0.05% 258
2025
Q1 		$253K Buy
17,040
+5,860
+52% +$82.1K 0.07% 241
2024
Q4 		$148K Buy
+11,180
New +$154K 0.04% 282

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

DGS Capital Management's TAK Position: Q1 2026 in Review

DGS Capital Management increased its Takeda Pharmaceutical (TAK) stake by 63% in Q1 2026, buying an estimated $157K and bringing the position to 23,106 shares worth $428K. The position accounts for 0.07% of the portfolio, ranked #277.

DGS Capital Management first reported a position in TAK in Q4 2024 and has held it in 6 quarters since. 361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

  • DGS Capital Management held 23,106 shares of Takeda Pharmaceutical worth $428K as of Q1 2026.
  • DGS Capital Management bought 8,936 Takeda Pharmaceutical shares in Q1 2026, an estimated $157K.
  • Takeda Pharmaceutical made up 0.07% of DGS Capital Management's portfolio in Q1 2026, its #277 holding.
  • DGS Capital Management first reported a position in Takeda Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.